// App-Quantinova.ai

PB1134 : Practical utilisation of Octapharma FVIII concentrates in previously untreated and minimally treated haemophilia A patients entering routine clinical treatment – The Protect-NOW Study

Researchers

Presenter

  • S. Halimeh

Principal Investigators

  • J. Oldenburg

  • R. Klamroth

  • M. Mathias

  • G. Hall

  • P. Marco Vera

  • M. Jansen

Medical Centers

  • Gerinnungszentrum Rhein-Ruhr, Duisburg, Nordrhein-Westfalen, Germany

  • University Clinic Bonn, Bonn, Nordrhein-Westfalen, Germany

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

  • Children's Hospital Oxford, Oxford Haemophilia and Thrombosis Comprehensive Care Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Departamento de Medicina Clínica. Universidad Miguel Hernández, Jefe de Servicio de Hematología y Hemoterapia, Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain

  • Octapharma Pharmazeutika Produktions GmbH, Vienna, Austria

Locations

  • Germany

  • United Kingdom

  • Spain

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03695978

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved